According to a news source, the Federal Trade Commission (FTC) may be planning to adopt a rule under expedited procedures to block patent settlements, known as “pay-for-delay” deals, between name-brand drug manufacturers and generic drug makers. Such deals are evidently reached when generic drug makers are paid to drop the patent lawsuits they file hoping to get their products to market more quickly. Citing unnamed sources, said that the rulemaking route is under consideration because the agency’s efforts to block the deals in court have failed and Congress has not taken action to make them illegal. While FTC spokesperson Peter Kaplan noted that the agency’s strategy is to fight the deals in court and seek legislation, he also said, “We are not dismissing any option out of hand.” See, June 9, 2011.